Samsung Biologics completed the acquisition of the remaining 50% stake in Samsung Bioepis from Biogen for $2.3bn.

Samsung Biologics, a South Korean biotechnology company, completed the acquisition of the remaining 50% stake in Samsung Bioepis joint venture from Biogen, an American multinational biotechnology company based in Cambridge, for $2.3bn. "We are thankful to Samsung Biologics for a productive collaboration since 2012. We believe biosimilars are essential to help sustain healthcare systems and represent an important value creation opportunity for Biogen," Michel Vounatsos, Biogen CEO.